Bayer Gets CHMP Backing for Higher-Dose Eylea in Two Major Retinal Eye Diseases
11 November 2023 - 2:00AM
Dow Jones News
By Colin Kellaher
Bayer on Friday said the European Medicines Agency's Committee
for Medicinal Products for Human Use has recommended approval of a
high-dose formulation of the blockbuster eye drug Eylea in two
major retinal eye diseases.
The German drugs-to-crops giant said the positive opinion covers
8-milligram doses of Eylea at extended treatment intervals of up to
every four months after three initial monthly doses in wet
age-related macular degeneration and diabetic macular edema.
Eylea, which Bayer is developing with Tarrytown, N.Y.,
biotechnology company Regeneron Pharmaceuticals, is currently
approved in Europe in a 2-milligram dose every eight weeks.
The European Commission, which generally follows the CHMP's
advice, is expected to make a decision in the coming months, Bayer
said.
Regeneron maintains exclusive rights to Eylea in the U.S., while
Bayer has licensed the exclusive marketing rights outside the U.S.,
where the companies equally split profits from sales of the
drug.
The U.S. Food and Drug Administration approved the high-dose
version of Eylea in August.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
November 10, 2023 09:45 ET (14:45 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Bayer (TG:BAYN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bayer (TG:BAYN)
Historical Stock Chart
From Apr 2023 to Apr 2024
